Responses

Download PDFPDF

Globalisation of clinical trials in oncology: a double-edged sword?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Globalization of Clinical Trials – Advocating for more trials in LMICs

    The work of Payedimarri et al.1, complemented by the insights of Jenei et al.2, has prompted substantial reflection. While the burgeoning involvement of low-middle-income countries (LMICs) in industry-funded research is a commendable trend, I concur with most criticisms articulated by these authors. Specifically, the challenge of limited access to studied agents within LMICs and the consequential absence of robust post-treatment care stand as significant concerns potentially affecting the outcomes of trials examining life-prolonging agents administered at earlier treatment stages3. However, a fundamental disagreement emerges regarding the framing of this issue and, notably, the assignment of responsibility for its resolution.

    Primarily, acknowledging that a substantial portion of innovative drugs trialed in LMICs often remains inaccessible to their populations post-trial, participation in a clinical trial offers an invaluable opportunity for patients, irrespective of their randomization into the interventional or control arm. The former might potentially receive a life-prolonging therapy, while the latter typically receives treatment comparable to or, in certain instances, superior to the prevailing standard of care in LMICs. Even with a limited patient enrollment, the impact of such treatment extends to these individuals and their families. Moreover, adherence to the stipulated standards in a clinical trial ensures that care aligns with trial expectations, often ma...

    Show More
    Conflict of Interest:
    DVA has received horaria from MSD, Libbs, Novartis, Ipsen. DVA has participated in as primary or sub-investigator of clinical research studies from the following sponsors: MSD, BMS, Pfizer, Roche, IMMiX, Nanoray, AstraZeneca, Merck Serono, Regeneron, Novartis, GSK